Published in J Immunol on September 12, 2012
B7 family checkpoint regulators in immune regulation and disease. Trends Immunol (2013) 1.53
B7x/B7-H4 modulates the adaptive immune response and ameliorates renal injury in antibody-mediated nephritis. Clin Exp Immunol (2015) 1.40
HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proc Natl Acad Sci U S A (2013) 1.12
Host b7x promotes pulmonary metastasis of breast cancer. J Immunol (2013) 1.05
Structure and cancer immunotherapy of the B7 family member B7x. Cell Rep (2014) 0.93
B7x and myeloid-derived suppressor cells in the tumor microenvironment: A tale of two cities. Oncoimmunology (2013) 0.82
Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy (2015) 0.81
Nardilysin-dependent proteolysis of cell-associated VTCN1 (B7-H4) marks type 1 diabetes development. Diabetes (2014) 0.80
Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy. Mol Ther (2016) 0.78
Loss of Peripheral Protection in Pancreatic Islets by Proteolysis-Driven Impairment of VTCN1 (B7-H4) Presentation Is Associated with the Development of Autoimmune Diabetes. J Immunol (2016) 0.77
The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3. Immunol Rev (2017) 0.77
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity (2007) 10.83
The PD-1 pathway in tolerance and autoimmunity. Immunol Rev (2010) 5.99
Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 5.78
B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol (2001) 4.10
The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol (2002) 3.47
B7-H4, a molecule of the B7 family, negatively regulates T cell immunity. Immunity (2003) 3.47
Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol (2003) 3.37
Multistep pathogenesis of autoimmune disease. Cell (2007) 3.36
Etiology of type 1 diabetes. Immunity (2010) 3.28
Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med (1994) 3.24
B7S1, a novel B7 family member that negatively regulates T cell activation. Immunity (2003) 3.18
The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol (2003) 3.18
Macrophage inflammatory protein-1. Int J Biochem Cell Biol (2004) 3.15
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A (2003) 3.02
Physiological beta cell death triggers priming of self-reactive T cells by dendritic cells in a type-1 diabetes model. J Exp Med (2003) 2.94
Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett (2002) 2.80
B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A (2003) 2.66
Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J Immunol (2004) 2.23
Peripheral tolerance of CD8 T lymphocytes. Immunity (2005) 2.21
Pancreatic lymph nodes are required for priming of beta cell reactive T cells in NOD mice. J Exp Med (2002) 2.02
B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res (2005) 1.94
B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. J Immunol (2002) 1.90
Individual nonobese diabetic mice exhibit unique patterns of CD8+ T cell reactivity to three islet antigens, including the newly identified widely expressed dystrophia myotonica kinase. J Immunol (2004) 1.86
Major histocompatibility complex class I-restricted T cells are required for all but the end stages of diabetes development in nonobese diabetic mice and use a prevalent T cell receptor alpha chain gene rearrangement. Proc Natl Acad Sci U S A (1998) 1.82
Alternatively activated macrophages induced by nematode infection inhibit proliferation via cell-to-cell contact. Eur J Immunol (2000) 1.78
Identification of a CD8 T cell that can independently mediate autoimmune diabetes development in the complete absence of CD4 T cell helper functions. J Immunol (2000) 1.77
Interferon-gamma is essential for destruction of beta cells and development of insulin-dependent diabetes mellitus. J Exp Med (1997) 1.67
IFN-gamma/TNF-alpha synergism as the final effector in autoimmune diabetes: a key role for STAT1/IFN regulatory factor-1 pathway in pancreatic beta cell death. J Immunol (2001) 1.55
How interferon-gamma keeps autoimmune diseases in check. Trends Immunol (2008) 1.53
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol (2010) 1.44
A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. J Immunol Methods (2001) 1.41
Characterization of human inducible costimulator ligand expression and function. J Immunol (2000) 1.38
In situ beta cell death promotes priming of diabetogenic CD8 T lymphocytes. J Immunol (2002) 1.30
The molecular signature of CD8+ T cells undergoing deletional tolerance. Blood (2009) 1.27
Altered chemokine levels in individuals at risk of Type 1 diabetes mellitus. Diabet Med (2006) 1.23
The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion. J Biomed Biotechnol (2011) 1.22
CD8+ cells enhance resistance to pulmonary serotype 3 Streptococcus pneumoniae infection in mice. J Immunol (2010) 1.17
Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type I diabetes. J Immunol (2000) 1.16
Genetic predisposition to autoimmunity--what have we learned? Semin Immunol (2011) 1.15
Tissue-specific expression of B7x protects from CD4 T cell-mediated autoimmunity. J Exp Med (2011) 1.14
Cutting edge: anti-inflammatory properties of low levels of IFN-gamma. J Immunol (2002) 1.13
Local expression of B7-H4 by recombinant adenovirus transduction in mouse islets prolongs allograft survival. Transplantation (2009) 1.10
Identification of a novel susceptibility locus for juvenile idiopathic arthritis by genome-wide association analysis. Arthritis Rheum (2009) 1.09
The role of perforin and granzymes in diabetes. Cell Death Differ (2009) 1.04
Reciprocal expression of co-stimulatory molecules, B7-1 and B7-2, on murine T cells following activation. Eur J Immunol (1995) 1.02
Enhanced pathogenicity of diabetogenic T cells escaping a non-MHC gene-controlled near death experience. J Immunol (2004) 1.01
B7-H4 Treatment of T Cells Inhibits ERK, JNK, p38, and AKT Activation. PLoS One (2012) 1.00
Requirement for both H-2Db and H-2Kd for the induction of diabetes by the promiscuous CD8+ T cell clonotype AI4. J Immunol (2004) 0.96
Early treatment of NOD mice with B7-H4 reduces the incidence of autoimmune diabetes. Diabetes (2011) 0.96
Overexpression of class I major histocompatibility complex accompanies insulitis in the non-obese diabetic mouse and is prevented by anti-interferon-gamma antibody. Diabetologia (1991) 0.92
B7-H4 transfection prolongs beta-cell graft survival. Transpl Immunol (2009) 0.91
Evidence that Cd101 is an autoimmune diabetes gene in nonobese diabetic mice. J Immunol (2011) 0.88
T cell costimulation and coinhibition: genetics and disease. Discov Med (2011) 0.85
Possible involvement of soluble B7-H4 in T cell-mediated inflammatory immune responses. Biochem Biophys Res Commun (2009) 0.83
Interaction of T-cell and antigen presenting cell co-stimulatory genes in childhood IgE. Eur Respir J (2009) 0.81
Restoring function in exhausted CD8 T cells during chronic viral infection. Nature (2005) 28.04
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med (2012) 11.14
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science (2009) 9.29
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature (2012) 7.76
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res (2009) 6.83
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer (2011) 6.44
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20
Autonomic nerve development contributes to prostate cancer progression. Science (2013) 6.11
Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet (2007) 5.68
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest (2006) 5.62
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A (2003) 5.49
Epitope landscape in breast and colorectal cancer. Cancer Res (2008) 5.29
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med (2010) 4.90
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med (2009) 4.68
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol (2003) 4.56
CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol (2002) 4.48
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res (2005) 4.23
Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 4.09
Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med (2010) 4.07
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A (2008) 3.80
Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Proc Natl Acad Sci U S A (2003) 3.75
Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection. J Immunol (2007) 3.25
Aire-dependent thymic development of tumor-associated regulatory T cells. Science (2013) 3.23
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med (2011) 3.12
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol (2006) 3.12
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc Natl Acad Sci U S A (2003) 3.02
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
Expression of Helios in peripherally induced Foxp3+ regulatory T cells. J Immunol (2011) 2.80
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 2.71
Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity (2002) 2.71
B7x: a widely expressed B7 family member that inhibits T cell activation. Proc Natl Acad Sci U S A (2003) 2.66
Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J Exp Med (2008) 2.60
The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res (2007) 2.54
Chitinase and Fizz family members are a generalized feature of nematode infection with selective upregulation of Ym1 and Fizz1 by antigen-presenting cells. Infect Immun (2005) 2.51
B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A (2007) 2.37
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Proteases in parasitic diseases. Annu Rev Pathol (2006) 2.26
Immune modulation in cancer with antibodies. Annu Rev Med (2013) 2.23
B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity (2004) 2.21
TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo. J Exp Med (2010) 2.20
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med (2013) 2.13
Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci U S A (2010) 2.12
Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev (2008) 2.08
Repeating blood cultures in neutropenic children with persistent fevers when the initial blood culture is negative. Pediatr Blood Cancer (2012) 2.07
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev (2011) 2.02
Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science (2008) 1.99
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol (2010) 1.98
Cordyceps fungi: natural products, pharmacological functions and developmental products. J Pharm Pharmacol (2009) 1.95
Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol (2009) 1.94
Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood (2009) 1.93
T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface. Immunity (2007) 1.92
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res (2007) 1.86
Individual nonobese diabetic mice exhibit unique patterns of CD8+ T cell reactivity to three islet antigens, including the newly identified widely expressed dystrophia myotonica kinase. J Immunol (2004) 1.86
T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine. Immunity (2011) 1.85
Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood (2012) 1.81
CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood (2008) 1.81
Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors. Cancer Res (2009) 1.77
Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One (2011) 1.73
Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol (2004) 1.71
Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS). Curr Opin Immunol (2010) 1.68
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc Natl Acad Sci U S A (2012) 1.64
Mast cell-mediated remodeling and fibrinolytic activity protect against fatal glomerulonephritis. J Immunol (2006) 1.63
B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections]. J Immunol (2004) 1.60
Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease. Semin Immunopathol (2010) 1.58
HLA-A*0201-restricted T cells from humanized NOD mice recognize autoantigens of potential clinical relevance to type 1 diabetes. J Immunol (2006) 1.58
Therapeutic helminth infection of macaques with idiopathic chronic diarrhea alters the inflammatory signature and mucosal microbiota of the colon. PLoS Pathog (2012) 1.52
The preferential ability of B lymphocytes to act as diabetogenic APC in NOD mice depends on expression of self-antigen-specific immunoglobulin receptors. Eur J Immunol (2002) 1.50
Selective delivery of beta cell antigen to dendritic cells in vivo leads to deletion and tolerance of autoreactive CD8+ T cells in NOD mice. Proc Natl Acad Sci U S A (2008) 1.49
Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res (2011) 1.47
Strength of TCR-peptide/MHC interactions and in vivo T cell responses. J Immunol (2011) 1.47
Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol Rev (2009) 1.47
Functional evidence for the mediation of diabetogenic T cell responses by HLA-A2.1 MHC class I molecules through transgenic expression in NOD mice. Proc Natl Acad Sci U S A (2002) 1.45
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol (2010) 1.44
Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients. Breast Cancer Res (2012) 1.43
IL-22+ CD4+ T cells are associated with therapeutic trichuris trichiura infection in an ulcerative colitis patient. Sci Transl Med (2010) 1.42
Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood (2010) 1.41
By altering ocular immune privilege, bone marrow-derived cells pathogenically contribute to DBA/2J pigmentary glaucoma. J Exp Med (2003) 1.39
Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. J Immunol (2005) 1.34
Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. J Exp Med (2012) 1.32
R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. Pediatr Blood Cancer (2010) 1.31
Monoclonal antibodies in cancer therapy. Cancer Immun (2012) 1.31